Background. The age at which passively acquired antibodies are lost is critical to
determining the optimal age for measles vaccination. Little is known about the influence of …

Background. Achieving the level of population immunity required for measles elimination
may be difficult in regions of high human immunodeficiency virus type 1 (HIV-1) prevalence …

Background. Previously, we demonstrated that measles antibody prevalence was lower at
age 12 months among children infected with human immunodeficiency virus (HIV) than …

Abstract Background. The World Health Organization recommends that infants at high risk
for developing measles before 9 months of age, including human immunodeficiency virus …

Abstract Background. PACTG (Pediatric AIDS Clinical Trials Group) 225, a multicenter,
randomized, open-label trial in the United States evaluated reactogenicity and …

Objectives. The goals of this study were to evaluate the proportion of previously vaccinated
human immunodeficiency virus (HIV) type 1-infected children with detectable …

An increase in illness due to measles is one of the potential consequences of the human
immunodeficiency virus (HIV) epidemic in Africa. During a study of perinatal HIV …

Measles infection remains a serious threat to child survival in the developing world despite
vaccination and treatment with vitamin A. This report reviews the epidemiology of measles in …

Methods: Infants aged 6–12 weeks were enrolled. This included HIV-uninfected infants born
to HIV-uninfected (HUU) and HIV-infected mothers (HEU). Additionally, we enrolled …

Background. Measles control may be more challenging in regions with a high prevalence of
HIV infection. HIV-infected children are likely to derive particular benefit from measles …